Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Asthma in Children, Exercise Induced Ast...
Phase NA
Enrollment 39
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is a common childhood disease that is characterized by chronic airway inflammation and episodic expiratory airflow obstruction. Asthma symptoms can impair participation in play and sports and have a negative impact on quality of life. It can be challenging for children to adequately feel and report their symptoms. Some children experience more symptoms than expected based on lung function during these symptoms, whereas others experience less symptoms than expected. This is also called 'symptom perception'. A tool was developed to visualize symptoms, lung function and accessory symptom perception: The Rainbow tool. The aim of this study was to identify asthmatic children with a poor perception and investigate if their symptom perception could be improved by regular lung function measurements and personal feedback based on the Rainbow Tool. Hypothesis: Measuring lung function en symptoms and provide personal feedback on perception based on the Rainbow tool has a positive effect on perception of asthma-related symptoms in asthmatic children.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Behavioral: Rainbow tool — The Rainbow tool visualizes perception based on lung function measurements and VAS scores.
  • Behavioral: Feedback — Feedback sessions with health care professional based on the Rainbow tool.

Primary Outcomes

  • Perception score (Two week run-in versus last week of intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-16
Completion: 2025-05-01
Eligibility
Age: 7 Years – 15 Years
Sex: ALL
Volunteers: false
Enrollment: 39 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medisch Spectrum Twente
Principal Investigators:
  • Vera Hengeveld, MD (PRINCIPAL_INVESTIGATOR) - Medisch Spectrum Twente
Contact Information
Study Contact:
Vera Hengeveld, MD
+31534872310
vera.hengeveld@mst.nl
Mattienne van der Kamp, MSc, PhD
+31534872310
m.vanderkamp@mst.nl
Vera Hengeveld, MD
+316534872310
vera.hengeveld@mst.nl
Medisch Spectrum Twente
Interventions
  • Behavioral: Rainbow tool — The Rainbow tool visualizes perception based on lung function measurements and VAS scores.
  • Behavioral: Feedback — Feedback sessions with health care professional based on the Rainbow tool.
Study Locations (1 sites)
Medisch Spectrum Twente, Enschede, Overijssel 7512 KZ Netherlands
Eligibility Criteria
Inclusion Criteria: Selection phase: * Pediatrician diagnosed asthma * Health care professional thinks perception might be poor * Age 7 until 15 years old * Adequate understanding of Dutch language Intervention phase: * Adequate number of lung function measurements + VAS scores during selection phase, defined as: * At least 4 measurements after exercise or when experiencing symptoms and * At least 2 standard measurements * Poor perception during selection phase, defined as: * At least 1 measurement in red zone on Perception Rainbow and/or * At least 2 measurements in orange zone on Perception Rainbow and/or * Average of all measurements after exercise or when experiencing symptoms in yellow zone (or orange/red)and/or * Average of all measurements in yellow zone (or orange/red) Exclusion Criteria: * Severe comorbidity (for example psychomotor retardation or severe cardiopulmonary conditions) * Not able to fill in VAS score (for example due to blindness) * Not able to perform technically correct spirometry manoeuvres * Medication change in past 2 weeks * Exacerbation which required oral prednisone in the past 6 weeks * Exacerbation at the moment of inclusion * No device (computer, tablet or smartphone) with internet connection available at home
Conditions Asthma, Telemedicine, Adherence, Treatme...
Phase NA
Enrollment 108
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Introduction: Asthma is one of the most common chronic respiratory diseases worldwide. Despite the extensive knowledge of the condition and available therapeutic options, severe asthmatic patients have poor disease control in 50% of cases. Objective: To assess the impact of implementing a mobile application (ESTOI) in patients diagnosed with asthma on disease control, treatment adherence, and perceived quality of life. Methodology: A 52-week randomized clinical trial involving asthma patients receiving care at a highly specialized hospital in Spain. A total of 108 patients will be included and divided into two groups. The intervention group will receive more comprehensive monitoring than usual, including access to the ESTOI application. The Asthma Control Test (ACT) questionnaire will be used as the primary assessment variable. Other variables to be studied include the Inhaler Adherence Test (TAI), the number of exacerbations, peak expiratory flow, exhaled nitric oxide examination, hospital anxiety and depression scale, asthma quality of life questionnaire, forced spirometry parameters (FVC, FEV1, and reversibility), and analytical parameters (eosinophilia and IgE).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: The mobile application ESTOI for Asthmatic patients — The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs: 1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities. 2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms. 3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan. 4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home. 5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs. 6. MESSAGING, it is a bidirectional contact area.

Primary Outcomes

  • Asthma Control Test (ACT) (Visit 1 (week 0), visit 2 (week 26) and visit 3 (week 52))
  • Number of exacerbations (Visit 1 (week 0), visit 2 (week 26) and visit 3 (week 52).)
  • Peak Expiratory Flow (PEF) (Visit 1 (week 0), visit 2 (week 26) and visit 3 (week 52))
  • Forced expiratory volume in one second (FEV1) (Visit 1 (week 0), visit 2 (week 26) and visit 3 (week 52))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 108 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Universitari de Bellvitge
Principal Investigators:
  • Héctor Cabrerizo Carreño, M.N (PRINCIPAL_INVESTIGATOR) - Hospital Universitari de Bellvitge
  • Mariana M Muñoz, M.D. (STUDY_DIRECTOR) - Hospital Universitari de Bellvitge
Contact Information
Study Contact:
Héctor Cabrerizo Carreño, M.N
+34 677281333
hectorc95@gmail.com
Interventions
  • Device: The mobile application ESTOI for Asthmatic patients — The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs: 1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities. 2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms. 3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan. 4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home. 5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs. 6. MESSAGING, it is a bidirectional contact area.
Study Locations (1 sites)
Bellvitge University Hospital, Barcelona, Barcelona 08907 Spain
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years with a diagnosis of asthma based on GEMA 5.2 2022. * Patients seen in the pulmonology service of the center. * Patients who have not previously received asthma education. * Capable of giving signed informed consent. Exclusion Criteria: * Patient who does not have a mobile device with Android or IOS system. * Lack of minimum technological knowledge for the use of the application (ESTOI). * People who are participating or have participated in a clinical trial in the last 6 months. * Patients diagnosed with other respiratory diseases except for obstructive sleep apnea (OSA), Asthma-COPD overlap syndrome (ACOS). * Patients with palliative or severe chronic illnesses that limit their life expectancy.
Conditions Asthma
Phase PHASE3
Enrollment 408
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This study is a phase III study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: SHR-1905 Injection — SHR-1905 injection.
  • Drug: SHR-1905 Placebo Injection — SHR-1905 placebo Injection.

Primary Outcomes

  • Annual asthma exacerbation rate (During 48 weeks of treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-09-03
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 408 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Contact Information
Study Contact:
Zhou Li
+86-020-62726806
zhou.li.zl69@hengrui.com
Nanshan Zhong
+86-020-83062893
nanshan@vip.163.com
The First Affiliated Hospital of Guangzhou Medical University
Xinyan Yang
+86-020-81567196
iceyxy@126.com
The First Affiliated Hospital of Guangzhou Medical University
Interventions
  • Drug: SHR-1905 Injection — SHR-1905 injection.
  • Drug: SHR-1905 Placebo Injection — SHR-1905 placebo Injection.
Study Locations (1 sites)
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510830 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18. 2. Documented physician-diagnosed asthma for at least 12 months. 3. Participants who have received asthma controller medication with medium or high dose ICS for at least 6 months. 4. Documented treatment with a total daily dose of either medium or high dose ICS (Refer to Guidelines for the prevention and management of bronchial asthma (2024 edition)) for at least 3 months. 5. At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months. 6. Pre-BD FEV1 \< 80% predicted normal. 7. Objective evidence of asthma as documented. 8. Documented history of at least 2 asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS. 9. ACQ-6 score ≥ 1.5 at screening and on day of baseline. 10. ePRO adherence ≥ 70% in the 7 days prior to randomization. Exclusion Criteria: 1. Clinically significant pulmonary disease other than asthma. 2. History of cancer. 3. History of a clinically significant infection. 4. Current smokers or participants with smoking history ≥ 10 pack-yrs. 5. History of chronic alcohol or drug abuse within 12 months. 6. Hepatitis B, C or HIV. 7. Pregnant or breastfeeding. 8. History of anaphylaxis following any biologic therapy. 9. participant randomized in the current study or previous SHR-1905 studies.
Conditions Asthma
Phase NA
Enrollment 54
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

To compare effects of Alternate Nostril Breathing exercise with incentive spirometer on lung functions (forced vital capacity, forced expiratory volume, and peak expiratory flow rate) in Asthma patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Alternate nostril breathing with Incentive Spirometery — Participants in experimental group were instructed to close their left nostril by left index finger and inhale through their right nostril for six seconds, then closing the right nostril and holding breath for six seconds. Afterward, they exhaled through the left nostril slowly for six seconds. Next, they inhaled through left nostril, keeping the right nostril closed for six seconds then hold the breath by closing both nostrils for six seconds subsequently, and then exhaled through the right nostril, keeping the left closed for six seconds repeating these steps several times for 10 minutes
  • Other: Incentive spirometery — The control group participants were asked to do breathing exercise with incentive spirometry. The subject is asked to create a tight seal around the mouthpiece and asked to inhale deeply and slowly and the subject would observe the flow meter for visual feedback of his/her effort. At the end of the inspiration the subject is asked to sustain the inhalation 2-3 seconds to facilitate the Inspiratory hold. Subject relaxes the seal around the mouthpiece and exhales. Normal breathing is taken, then the exhalation phase in the incentive spirometry is done and the whole cycle is repeated 5 - 10 times thrice a day over a period 6 weeks

Primary Outcomes

  • Forced expiratory volume in 1 second (6 week)
  • Forced Vital Capicity (6 week)
  • Peak Expiratory Flow Rate (6 week)
  • Asthama Control Test (6 week)
  • Asthama Quality of Life Questionaire with standardized Activities (6 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-20
Completion: 2025-11
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Riphah International University
Principal Investigators:
  • Muhammad Iqbal Tariq, PhD* (PRINCIPAL_INVESTIGATOR) - Riphah International University
Contact Information
Study Contact:
Muhammad Iqbal Tariq, PhD*
03338236752
iqbal.tariq@riphah.edu.pk
Hira Qazi, MSPT
+92 319 5523996
hiraqazi5sem@gmail.com
Allied Specialist Hospital & Clinics
Hira Qazi, MSPT
Allied Specialist Hospital & Clinics
Interventions
  • Other: Alternate nostril breathing with Incentive Spirometery — Participants in experimental group were instructed to close their left nostril by left index finger and inhale through their right nostril for six seconds, then closing the right nostril and holding breath for six seconds. Afterward, they exhaled through the left nostril slowly for six seconds. Next, they inhaled through left nostril, keeping the right nostril closed for six seconds then hold the breath by closing both nostrils for six seconds subsequently, and then exhaled through the right nostril, keeping the left closed for six seconds repeating these steps several times for 10 minutes
  • Other: Incentive spirometery — The control group participants were asked to do breathing exercise with incentive spirometry. The subject is asked to create a tight seal around the mouthpiece and asked to inhale deeply and slowly and the subject would observe the flow meter for visual feedback of his/her effort. At the end of the inspiration the subject is asked to sustain the inhalation 2-3 seconds to facilitate the Inspiratory hold. Subject relaxes the seal around the mouthpiece and exhales. Normal breathing is taken, then the exhalation phase in the incentive spirometry is done and the whole cycle is repeated 5 - 10 times thrice a day over a period 6 weeks
Study Locations (1 sites)
Allied Specialist Hospital & Clinics, Abbottābād, Khyber PkahtoonKhwa 22020 Pakistan
Eligibility Criteria
Inclusion Criteria: * Diagnosed male \&amp; female asthma patients of age 18-60 years. * Patients with mild to moderate asthma having predicted FEV1 between 60-80%. * Stable asthma condition without recent exacerbations. * Able to perform spirometry and follow instructions for the interventions. * No recent respiratory infections. Exclusion Criteria: * Patients with severe asthma (FEV1 \&lt; 60% predicted). * Patients having respiratory infections, recent exacerbations or other comorbidities. * Inability to perform breathing exercises or spirometry. * Patients using medications like oral steroids, beta blockers. * Pregnant women due to potential risks with breathing exercises.
Conditions Allergy
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to identify and assess in real time the impact of the combined action of various types of air and dust pollutants within a classroom on children's health and quality of life, particularly regarding atopic/allergic diseases in children, and on potential exposure to pollutants at home. Participants will answer questionnaires regarding their health and medications, undergo allergy tests, perform non-invasive lung function tests and check blood oxygen levels.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Standardized questionnaires — Baseline questionnaires for cases and follow-up questionnaires for cases and controls will be completed to collect data on sociodemographic characteristics, health outcomes, potential risk factors, lifestyle, and living environment.
  • Other: Lung function tests — All participants, including cases and controls, will undergo comprehensive spirometry testing, pulse oximetry assessment, and fractional exhaled nitric oxide (FeNO) measurement.
  • Diagnostic Test: Prick tests — Cases and controls will undergo skin prick testing for common allergens, including house dust mites, cat, dog, Alternaria, cypress, birch, plane tree (Platanus), grass, latex, olive tree, ragweed, and mugwort,...
  • Other: Biological samples — Subjects and their parents/guardians will be given the option to provide blood, urine, and nasopharyngeal samples.
  • Device: Portable sensors — Up to 10 subjects ( with their parents/guardians consent) will be given the option to use CANARIN devices, to monitor at the individual level exposures to air pollutants (PM and VOC) and other environmental factors (temperature, humidity, pressure) in and outside school.

Primary Outcomes

  • Statistically significant differences in spirometric parameter, Peak Flow, between case and control groups (10 Months)
  • Statistically significant differences in FeNO measurements between case and control groups (10 Months)
  • Evaluation of statistically significant differences in spirometric parameter, FEV, between case and control groups (10 months)
  • Evaluation of statistically significant differences in spirometric parameter, FVC, between case and control groups (10 months)
  • Statistically significant differences in the spirometric parameter, FEV₁/FVC ratio, between case and control groups (10 months)
  • Statistically significant differences in spirometric parameter, FEF, between case and control groups (10 months)
  • Evaluation of statistically significant differences in spirometric parameter, mean forced expiratory flow, between case and control groups (10 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-04
Completion: 2026-06
Eligibility
Age: 8 Years – 12 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Montpellier
Contact Information
Study Contact:
Dr CAIMMI, MD
+33467336107
dp-caimmi@chu-montpellier.fr
CHU Montpellier
Interventions
  • Other: Standardized questionnaires — Baseline questionnaires for cases and follow-up questionnaires for cases and controls will be completed to collect data on sociodemographic characteristics, health outcomes, potential risk factors, lifestyle, and living environment.
  • Other: Lung function tests — All participants, including cases and controls, will undergo comprehensive spirometry testing, pulse oximetry assessment, and fractional exhaled nitric oxide (FeNO) measurement.
  • Diagnostic Test: Prick tests — Cases and controls will undergo skin prick testing for common allergens, including house dust mites, cat, dog, Alternaria, cypress, birch, plane tree (Platanus), grass, latex, olive tree, ragweed, and mugwort,...
  • Other: Biological samples — Subjects and their parents/guardians will be given the option to provide blood, urine, and nasopharyngeal samples.
  • Device: Portable sensors — Up to 10 subjects ( with their parents/guardians consent) will be given the option to use CANARIN devices, to monitor at the individual level exposures to air pollutants (PM and VOC) and other environmental factors (temperature, humidity, pressure) in and outside school.
Study Locations (1 sites)
CHU Montpellier, Montpellier, France
Eligibility Criteria
Inclusion Criteria: * Child included in the SynAir-G observational study * Child and caregiver(s) willing to follow the study procedures * Written informed consent from the child's parents/guardians * For case group, at least one positive answer (yes) to any of the following questions and for control group, negative answers to all the following questions based on the baseline questionnaire administered in the SynAir-G observational study, as shown below.: a. General health i. Does your child have any health problems (if yes to asthma, allergic rhinitis /rhino-conjunctivitis, atopic dermatitis)? b. Asthma i. Has your child ever had wheezing or whistling in the chest in the past 12 months? ii. In the past 12 months, has your child's chest sounded wheezy during or after exercise? iii. In the past 12 months, has your child had a dry cough at night, apart from a cough associated with a cold or chest infection? c. Rhinitis i. In the past 12 months has your child had a problem with sneezing, or a runny, or blocked nose when she/he DID NOT have a cold or the flu? d. Eczema (both answers yes) i. Has your child had this itchy rash at any time in the past 12 months? If so, has this itchy rash at any time affected any of the following places: the folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes? e. Food allergy i. Has your child had diagnosed food allergy during last 12 months? * For case group: Diagnosis of asthma/allergic rhinitis/eczema/food allergy (based on SYNAIR-G baseline questionnaire), active during the past year. * For control group: absence of diagnosis of asthma/allergic rhinitis/eczema/food allergy (based on SYNAIR-G baseline questionnaire) Exclusion Criteria: * Child or child's parents/guardians who: 1. Refuse to participate in the project / to give informed consent. 2. Do not want to follow the protocol procedures. 3. Do not read or/and write in French. 4. Plan a long stay outside the region that does not allow them to follow the visit plan. 5. The child is not affiliated to the French social security service
Conditions Bipolar Disorder (BD), Bipolar Disorder ...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized controlled trial investigating the effects of an 8-TRE intervention compared to a wait list (control) on metabolic health and body composition in people diagnosed with BD and who are currently obese and at least mildly depressed. Following a 1-week baseline assessment, participants will be randomized to either a TRE or the wait list (1-to-1 ratio) for 8 weeks. At baseline, Week 8 (post treatment), and Week 20 (follow-up), investigators will assess daily eating patterns for one week, followed by collection of fasting lipids, body weight and vital signs. At Week 4 (i.e., mid-treatment), the investigators will assess self-reported outcomes only. Participants assigned to the wait list condition will have the option of receiving the TRE intervention after 20 weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Time Restricted Eating — See arms description

Primary Outcomes

  • Weight Loss (Week 0, Week 8, Week 20)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-01
Completion: 2027-09-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Brigham and Women's Hospital
Principal Investigators:
  • Louisa G. Sylvia, PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Giuliana M Chau
16176439923
gchau1@mgh.harvard.edu
Giuliana Chau
617-643-9923
gchau1@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Other: Time Restricted Eating — See arms description
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * Adults (aged 18-65 years) * Diagnosed with bipolar disorder (i.e., subtype Bipolar I or II as assessed with the Quick SCID)21 * Currently experiencing depression (i.e., PHQ-9 ≥ 10)22 * Currently overweight (i.e., Body mass index (BMI) \> 30 kg/m2) * Provides Informed Consent Exclusion Criteria: 1. Dietary factors: 1. Diagnosis, or strong clinical suspicion, of eating disorders, including but not limited to, anorexia nervosa, bulimia nervosa, binge eating disorder (as assessed with the Quick SCID) 2. Concurrent dietary intervention or modification unrelated to study procedures 2. Psychiatric factors: 1. Severe depression (i.e., PHQ-9\>20) 2. Experiencing manic symptoms (i.e., ASRM \< 6)23 3. Active suicidal ideation (i.e., PHQ-9, item 9 \>2) 4. Current alcohol/substance use disorder (as assessed with the Quick SCID) 3. Medical factors: 1. Use of weight loss medications or supplements 2. Use of medications that may cause weight loss or gain, unless body weight and medication usage remained stable for at least 6 months 3. Previous weight loss surgery 4. Malignancy within past 2 years 5. Major surgery within past 3 months 6. Medical instability considered to interfere with study procedures 7. Use of medications that have the potential to cause hypoglycemia (e.g., insulin, sulfonylureas) 8. Undergoing treatment for cancer 9. Use of medications for which time restricted eating would interfere with recommended timing of medication ingestion with food intake. 4. Lifestyle and other factors: a. Work or social schedules that would impede ability to adhere to study protocol 5. Adherence factors: 1. Ability to adhere to study procedures
Conditions Depressive Disorder
Phase NA
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to compare the reduction in the severity of depression after a duration of 06 weeks between patients receiving conventional therapy (antidepressant; Sertraline) only and those receiving both conventional therapy and a structured aerobic exercise (cycling, brisk walking).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Structured Aerobic exercise — Participants will receive structured, supervised aerobic exercise ( cycling, brisk walking), in addition to conventional treatment consisting of 03 sessions per week, 35 minutes each for 06 weeks.

Primary Outcomes

  • Change in Beck Depression Inventory (BDI) score (Baseline to 06 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-02-01
Eligibility
Age: 18 Years – 55 Years
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Manahil Gill
Contact Information
Study Contact:
Manahil Gill, MBBS
+92 304 6527981
manahilgill143@gmail.com
Muhammad Ahsan Mustafa, MBBS
+ 92 333 3396180
Manahil Gill, MBBS
+92 304 6527981
manahilgill143@gmail.com
CMH Bahawalpur
Interventions
  • Behavioral: Structured Aerobic exercise — Participants will receive structured, supervised aerobic exercise ( cycling, brisk walking), in addition to conventional treatment consisting of 03 sessions per week, 35 minutes each for 06 weeks.
Study Locations (1 sites)
CMH Bahawalpur, Chak Four Hundred Fifty-four, Punjab Province 63100 Pakistan
Eligibility Criteria
Inclusion Criteria: i. All new patients diagnosed with moderate and severe depression using BDI scale according to ICD-11 criteria between the ages of 18-55 years. ii. Both genders will be included. Exclusion Criteria: i. Patients with severe physical disabilities such as Spinal cord injuries, severe osteoporosis or medical conditions that prevent exercise such as ischemic changes in ECG pre-exercise. ii. Pregnant females. iii. Individuals already engaging in physical activities like athletes.
Conditions Death Anxiety, Depression, Anxiety
Phase NA
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this experimental study is to investigate the transdiagnostic role of death anxiety in depression and anxiety symptoms in participants from the general population. The main questions it aims to answer are: 1. Does the mortality salience task induce death anxiety? 2. Does the experimental group present an increase in depression and anxiety symptoms following the mortality salience task? The investigators will compare the experimental condition to a control condition to see if the death anxiety induction is responsible for the expected increase in depression and anxiety symptoms. The mortality salience prompt will be asking participants to elaborate on their thoughts and feelings surrounding death and dying, including what they think happens during death. The dental pain prompt will ask participants to do the same, only in regards to the thought of having dental pain. Experimental group: participants will undergo a pen-and-paper writing task where they will be asked to answer two questions: 1. "Please briefly describe the emotions that the thought of your own death arouses in you." 2. "Jot down, as specifically as you can, what you think will happen to you physically as you die and once you are physically dead." Control group: 1. "Please briefly describe the emotions that the thought of dental pain arouses in you." 2. "Jot down, as specifically as you can, what you think happens to you physically as you experience dental pain and once you have physically experienced dental pain."

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Mortality Salience Prompts — This intervention implies giving two prompts to participants, in a written format, while asking them to write out answers to the given prompts. The first prompt is: "Please briefly describe the emotions that the thought of your death arouses in you." The second prompt is "Jot down, as specifically as you can, what you think will happen to you physically as you die and once you are physically dead."
  • Behavioral: Dental Pain Prompts — This intervention implies giving two prompts to participants, and requesting that participants write out their answers to these prompts. The first prompt is: "Please briefly describe the emotions that the thought of dental pain arouses in you." The second prompt is: "Jot down, as specifically as you can, what you think happens to you physically as you experience dental pain and once you have physically experienced dental pain."

Primary Outcomes

  • Collet-Lester Fear of Death Scale - Revised (CLFD-R) (Baseline (Day 1), After the experimental task (Day 14))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-01
Completion: 2026-01
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Babes-Bolyai University
Contact Information
Study Contact:
Roxana Cardoș, PhD
0040751477323
roxanaoltean@psychology.ro
Arnold C. Kun
0040751216916
kun.arnold.cristian@gmail.com
Roxana Cardoș, PhD
+40 751 477 323
roxanaoltean@psychology.ro
Babes Bolyai University
Interventions
  • Behavioral: Mortality Salience Prompts — This intervention implies giving two prompts to participants, in a written format, while asking them to write out answers to the given prompts. The first prompt is: "Please briefly describe the emotions that the thought of your death arouses in you." The second prompt is "Jot down, as specifically as you can, what you think will happen to you physically as you die and once you are physically dead."
  • Behavioral: Dental Pain Prompts — This intervention implies giving two prompts to participants, and requesting that participants write out their answers to these prompts. The first prompt is: "Please briefly describe the emotions that the thought of dental pain arouses in you." The second prompt is: "Jot down, as specifically as you can, what you think happens to you physically as you experience dental pain and once you have physically experienced dental pain."
Study Locations (1 sites)
Babes Bolyai University, Cluj-Napoca, Romania
Eligibility Criteria
Inclusion Criteria: * Age over 18 years. * Living in Cluj-Napoca (or otherwise willing and able to participate in the lab task) Exclusion Criteria: * Personality disorder diagnosis * Psychotic disorder diagnosis * Suicidal ideation
Conditions Major Depressive Disorder (MDD)
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

POWER project is a randomized, controlled, non-profit study with the primary objective of testing the effectiveness of non-pharmacological interventions-such as physical activity, cognitive training, and dietary supplementation-in reducing depressive symptoms and preventing or delaying cognitive impairments that frequently co-occur in individuals with Major Depressive Disorder (MDD).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Soybean oil (Standard treatment) — 3g/day of Soybean Oil
  • Dietary Supplement: Eicosapentaenoic acid (omega-3 fatty acid) — 3 grams/day

Primary Outcomes

  • Depressive Symptoms (Weeks 0, 4, 8, 12, 16, 24)
  • Depressive Symptoms (Weeks 0, 4, 8, 12, 16, 24)
  • Depressive Symptoms (Weeks 0, 4, 8, 12, 16, 24)
  • Depressive Symptoms (Weeks 0, 4, 8, 12, 16, 24)
  • Executive Functioning (Weeks 0, 4, 12, 24)
  • Executive Functioning (Weeks 0, 4, 12, 24)
  • Executive Functioning (Weeks 0, 4, 12, 24)
  • General Cognitive Ability and Memory & Attention (Weeks 0, 4, 12, 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2028-09
Eligibility
Age: 50 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Science and Technology Council, Taiwan
Collaborators: IRCCS Centro San Giovanni di Dio Fatebenefratelli, University College Cork
Contact Information
Study Contact:
Kuan_Pin Su, MD, PhD
+886 (04) 2205-2121
cobol@cmu.edu.tw
Mind Body Interface Research Center (MBI Lab & Care)
Interventions
  • Dietary Supplement: Soybean oil (Standard treatment) — 3g/day of Soybean Oil
  • Dietary Supplement: Eicosapentaenoic acid (omega-3 fatty acid) — 3 grams/day
Study Locations (1 sites)
Mind Body Interface Research Center (MBI Lab & Care), Taichung, Taichung 404 Taiwan
Eligibility Criteria
Inclusion Criteria: * Aged 50-80 years old * Major Depressive Disorder * Absence or mild cognitive impairment Exclusion Criteria: \-
Conditions Depressive Symptom
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

CADS-D aimes to evaluate the effectiveness and feasibility of a newly DCBT program for Chinese adolescents with depressive symptoms.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: Digital cognitive behavioral therapy(DCBT) — Moca is a mobile application designed to deliver structural CBT for adolescents with mood problems. Moca provides six-twelve guided sessions with an estimated proceeding duration of 25-45min each, developed to be processed weekly. The content of each session includes the introduction of the core concepts and principles of CBT, psychological counseling dialogue, skill exercises, and homework. Content presentation forms include text, animation, audio, comics, etc. At the end of each module, the participants will be asked to submit homework that will ask them to apply their learned skills to nursing or daily life situations that they personally perceive as stressful. Participants can review the completed sessions and record their mood status during the intervention period.
  • Other: Regular mental health curriculum — The content of regular mental health curriculum includes mental health education lecture. Few lectures address the knowledge and skills involved in CBT in such education lecture.

Primary Outcomes

  • Change in CDRS-R (Children's Depression Rating Scale) scores from baseline (Baseline of intervention period, 6 weeks, and 3 months follow-up (18 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-12
Completion: 2026-09
Eligibility
Age: 12 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Chongqing Medical University
Contact Information
Study Contact:
Xinyu Zhou, Professor
15823996993
zhouxinyu@cqmu.edu.cn
Xinyu Zhou, Professor
15823396993
zhouxinyu@cqmu.edu.cn
The First Affiliated Hospital of Chongqing Medical University
Interventions
  • Other: Digital cognitive behavioral therapy(DCBT) — Moca is a mobile application designed to deliver structural CBT for adolescents with mood problems. Moca provides six-twelve guided sessions with an estimated proceeding duration of 25-45min each, developed to be processed weekly. The content of each session includes the introduction of the core concepts and principles of CBT, psychological counseling dialogue, skill exercises, and homework. Content presentation forms include text, animation, audio, comics, etc. At the end of each module, the participants will be asked to submit homework that will ask them to apply their learned skills to nursing or daily life situations that they personally perceive as stressful. Participants can review the completed sessions and record their mood status during the intervention period.
  • Other: Regular mental health curriculum — The content of regular mental health curriculum includes mental health education lecture. Few lectures address the knowledge and skills involved in CBT in such education lecture.
Study Locations (1 sites)
The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016 China
Eligibility Criteria
Inclusion Criteria: 1. Age 12 to 18 years; 2. Scored 28 or higher on the children's depression rating scale-revised (CDRS-R); 3. Have the ability to read and write in Chinese; 4. Participant and at least one of their guardians provided written consent; 5. Have access to mobile phone and internet. Exclusion Criteria: 1. The researchers assessed that the adolescent's depressive symptoms were too severe to participate to CADS-D; 2. Scored 5 or higher on item 13 (suicidal ideation) on CDRS-R; 3. Participants who met diagnosis of other mental disorder except depression; 4. Severe physical illnesses or other physical disabilities that prevented the use of DCBT; 5. Within the past three months or currently undergoing any antidepressant treatment, including medication therapy, psychotherapy, and physical therapy; 6. Unavailability to follow up months after intervention.
Conditions Severe Depression, Moderate Depression, ...
Phase PHASE3
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: nebulized ketamine — The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
  • Drug: nebulized midazolam — The formulation of the active comparator drug is administered via nebulizer in which the participant inhales the study drug. The dosage is calculated by body weight (0.03mg/kg).

Primary Outcomes

  • Change in depressive symptoms on the Montgomery-Åsberg Depression Rating Scale (MADRS) (8-10 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-10-16
Completion: 2027-09-30
Eligibility
Age: 18 Years – 88 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Theresa Jacob, PhD, MPH
Principal Investigators:
  • Theresa Jacob, PhD, MPH (STUDY_DIRECTOR) - Maimonides Medical Center
Contact Information
Study Contact:
Jessica Poster, MD
718-283-8170
JPoster@maimo.org
Mayank Kumar, PhD
718-283-8170
Maykumar@maimo.org
Maimonides Medical Center
Hasan Mustafic, BA
718-283-8170
HMustafic@maimo.org
Maimonides Medical Center
Interventions
  • Drug: nebulized ketamine — The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
  • Drug: nebulized midazolam — The formulation of the active comparator drug is administered via nebulizer in which the participant inhales the study drug. The dosage is calculated by body weight (0.03mg/kg).
Study Locations (1 sites)
Maimonides Medical Center, Brooklyn, New York 11219 United States
Eligibility Criteria
Inclusion Criteria: * All individuals 18 years and older with a Montgomery-Asberg Depression Rating Scale score (MADRS) ≥ 20 * Must have a diagnosis of moderate to severe Major Depressive Disorder (MDD) * Structured Clinical Interview for DSM-5 (SCID-5) will be performed to confirm MDD diagnosis Exclusion Criteria: * Adult patients with an allergy to Ketamine * Adult patients with an allergy to Midazolam * Individuals with a history of mania/hypomania or diagnosis of bipolar disorder * Patients on lithium and/or lamotrigine therapy * Recent or current homicidal ideation with an intent to act * MDD with psychotic features or current or past diagnosis of a psychotic disorder * No substance use disorder in the preceding 3 months except nicotine or caffeine or a positive urine screen for substances (except cannabis) * Diagnosis of obsessive-compulsive disorder, antisocial personality disorder, borderline personality disorder, posttraumatic stress disorder, intellectual disability, altered mental status, pregnant or breastfeeding patients, * Patients on \> 2 medications for hypertension * Patients with uncontrolled hypertension (BP \>140 mm Hg systolic and/or \>90 mm Hg diastolic on two separate readings at the time of screening) * Body weight of \> 150kg * Patients with history of congestive cardiac failure * Day of presentation, patients with unstable vital signs (systolic blood pressure \<90 or\>160 mm Hg, pulse rate \<50 or \>150 beats/min, and respiration rate \<10 or \>30 breaths/min) * Consumption of opioids within 24 hours of drug administration * Acutely intoxicated patients will also be excluded
Conditions Stroke, Stress, Psychological, Post Trau...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Outpatient participants with a recent stroke diagnoses receive complimentary rehabilitation. The nature interventions include ergo- and physiotherapeutic and neurocognitive tasks with the support of an psychotherapeutic frame designed to be performed in a nature environment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Therapies in nature — Therapeutic tasks in nature specifically designed for the study

Primary Outcomes

  • The effect of nature interventions on PROMIS questionnaire (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Joint Authority for Päijät-Häme Social and Health Care
Collaborators: University of Helsinki, University of Jyvaskyla, Tampere University
Principal Investigators:
  • Hanna Haveri, MD PhD (PRINCIPAL_INVESTIGATOR) - Wellbeing Services County of Paijat-Hame
Contact Information
Study Contact:
Hanna Haveri, MD PhD
+358 3 81911
hanna.haveri@paijatha.fi
Marja Mikkelsson, Prof
+358 3 81911
marja.mikkelsson@paijatha.fi
Hanna Haveri, MD PhD
+358 3 81911
hanna.haveri@paijatha.fi
Joint Authority for Päijät-Häme Social and Health Care
Interventions
  • Behavioral: Therapies in nature — Therapeutic tasks in nature specifically designed for the study
Study Locations (1 sites)
Joint Authority for Päijät-Häme Social and Health Care, Lahti, 15850 Finland
Eligibility Criteria
Inclusion Criteria: * Acute stroke Exclusion Criteria: * Traumatic intracranial bleeding without stroke * A malign, aggressive disease * Severe aphasia or incapable of independent decision making